SYDNEY, AUSTRALIA--(Marketwired - April 29, 2014) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", the "Company") today released its Appendix 4C - Quarterly Report for the three month period ending 31 March 2014. The Company had A$26,737,000 in cash and term deposits as of the end of the quarter. The majority of funds spent during the quarter are related to development activities of Prima's lead product CVac™.
Prima's management will hold a conference call to present its quarterly financial results and provide an update on the Company's activities.
The call is scheduled for Tuesday the 6th of May 2014 at 9:00am (Sydney local time). This corresponds to Monday, the 5th of May at 7:00pm U.S. Eastern daylight time. The conference call dial-in numbers are as follows:
Australia Toll Free 1800 265 784
Australia Alternate Toll Free 1 800 131 617
Canada/USA 1 855 237 2970
Germany 0800 189 9369
The call will also be audio webcast with additional supplemental slides available via http://www.media-server.com/m/go/primabiomed-may2014. Before launching the webcast, it is recommended to click on the link and then on "test your systems configuration."
A replay and a transcript of the teleconference will be available through Prima's website following the live event.
About Prima BioMed
Prima BioMed is a globally active leader in the development of personalized immunocellular therapeutic products for the treatment of cancer. Prima is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Prima's lead product is CVac™, an autologous dendritic cell-based product currently in clinical trials. www.primabiomed.com.au